CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (ASX: XJO) fell 0.3% to begin the week, struggling to overcome a weak overseas lead with a lack of material announcements for the local market.
The CSL Limited (ASX:CSL) share price could be a long-term opportunity for investors. Is the healthcare biotech giant a good value buy today?
The S&P/ASX 200 (ASX: XJO) finished the week flat on Friday but managed to deliver a strong 2.4% gain despite just four days of trading.
Will the Flight Centre Travel Group Ltd (ASX: FLT) share price be safe after the Australian Government update about the AstraZeneca vaccine?
Concerns over the AstraZeneca vaccine affects the CSL (ASX: CSL) share price. Is it an over-reaction? Here’s my take.
The S&P/ASX 200 (ASX: XJO) and All Ordinaries (ASX: XAO) delivered another positive day on Thursday, both finishing 1.0% higher.
There’s a question mark about over the CSL Limited (ASX: CSL) share price with ongoing troubles with the COVID-19 vaccines.
There are a couple of great ASX blue chip shares that are growing globally. I’d want them in my portfolio if I were focused on large caps.
The ASX 200 (INDEXASX:XJO) is tipped to start the day in the green. Netwealth (ASX:NWL), Brickworks (ASX:BKW) and AMP Ltd (ASX:AMP) shares are in the news.
